Julio César Vega

Julio César Vega

Auto-generated profile, based on publicly available information

Julio César Vega

Laboratorio Pablo Cassará - I+D+i, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SBShruti Bansal
Shruti Bansal
CJColleen B. Jonsson
Colleen B. Jonsson
STShannon L. Taylor
Shannon L. Taylor
JFJuan Manuel Figueroa
Juan Manuel Figueroa
ADAndrea Vanesa Dugour
Andrea Vanesa Dugour
JVJulio César Vega
Julio César Vega
Last year observed a global pandemic caused by SARS-CoV-2 (severe acute respiratory syndrome-coronavirus 2) infection affecting millions of individuals worldwide. There is an urgent unmet need to provide an easily producible and affordable medicine to prevent transmission and provide early treatment for this disease. Since the nasal cavity and the rhinopharynx are the sites of initial replication of SARS-CoV-2, a nasal spray may be an effective option to target SARS-CoV-2 infection. In this study, we tested the antiviral action of three candidate nasal spray formulations against SARS-CoV-2in vitro. We determined that iota-carrageenan in concentrations as low as 6 μg/mL inhibits SARS-CoV-2in vitro. The concentrations of iota-carrageenan with activity against SARS-CoV-2in vitromay be easily achieved through the application of nasal sprays as commonly used in several countries. Recently a double-blind, placebo-controlled study showed that iota-carrageenan in isotonic sodium chloride reduces ca. five times the risk of infection by SARS-CoV-2 in health care personnel. Further, xylitol at a concentration of 50 mg/mL (ca. 329 mM) was found to exert some antiviral action, though this preliminary finding needs further confirmation.

21 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SBShruti Bansal
Shruti Bansal
CJColleen Jonsson
Colleen Jonsson
STShannon L. Taylor
Shannon L. Taylor
JFJuan Manuel Figueroa
Juan Manuel Figueroa
ADAndrea Vanesa Dugour
Andrea Vanesa Dugour
JVJulio César Vega
Julio César Vega
COVID-19 (coronavirus disease 2019) is a pandemic caused by SARS-CoV-2 (severe acute respiratory syndrome-coronavirus 2) infection affecting millions of persons around the world. There is an urgent unmet need to provide an easy-to-produce, affordable medicine to prevent transmission and provide early treatment for this disease. The nasal cavity and the rhinopharynx are the sites of initial replication of SARS-CoV-2. Therefore, a nasal spray may be a suitable dosage form for this purpose. The main objective of our study was to test the antiviral action of three candidate nasal spray formulations against SARS-CoV-2. We have found that iota-carrageenan in concentrations as low as 6 µg/ mL inhibits SARS-CoV-2 infection in Vero cell cultures. The concentrations found to be active in vitro against SARS-CoV-2 may be easily achieved by the application of nasal sprays already marketed in several countries. Xylitol at a concentration of 5 % m/V has proved to be viricidal on its own and the association with iota-carrageenan may be beneficial, as well.

2 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LCLorena M. Coria
Lorena M. Coria
JRJuan Manuel Rodriguez
Juan Manuel Rodriguez
ADAgostina Demaria
Agostina Demaria
LBLaura A. Bruno
Laura A. Bruno
MMMayra Rios Medrano
Mayra Rios Medrano
JCJuliana Cassataro
Juliana Cassataro
In the context of continuous emergence of SARS-CoV-2 variants of concern (VOCs), one strategy to prevent the severe outcomes of COVID-19 is developing safe and effective broad-spectrum vaccines. Here, we present preclinical studies of a RBD vaccine derived from the Gamma SARS-CoV-2 variant adjuvanted with Alum. The Gamma-adapted RBD vaccine is more immunogenic than the Ancestral RBD vaccine in terms of inducing broader neutralizing antibodies. The Gamma RBD presents more immunogenic B-cell restricted epitopes and induces a higher proportion of specific-B cells and plasmablasts than the Ancestral RBD version. The Gamma-adapted vaccine induces antigen specific T cell immune responses and confers protection against Ancestral and Omicron BA.5 SARS-CoV-2 challenge in mice. Moreover, the Gamma RBD vaccine induces higher and broader neutralizing antibody activity than homologous booster vaccination in mice previously primed with different SARS-CoV-2 vaccine platforms. Our study indicates that the adjuvanted Gamma RBD vaccine is highly immunogenic and a broad-spectrum vaccine candidate.